Enfortumab vedotin-ejfv (D4053-GRP)

Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma.